Navigation Links
Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures
Date:12/6/2008

://www.jnjpharmarnd.com" target="_new">http://www.jnjpharmarnd.com.

About Ortho-McNeil Neurologics

Headquartered in Titusville, NJ, Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, focuses exclusively on providing solutions that improve neurological health. The company currently markets products for Alzheimer's disease, epilepsy and acute and preventive migraine treatment. In conjunction with internal and external research partners, Ortho-McNeil Neurologics continues to explore new opportunities to develop solutions for unmet health care needs in neurology.

Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the J&JPRD's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on
'/>"/>

SOURCE Ortho-McNeil Neurologics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... 20 Soligenix, Inc. (OTC... formerly known as DOR BioPharma, Inc., a late-sta...has formed a consortium to develop thermostable te...ting vaccines. Soligenix received a $9.4 million g...fectious Diseases (NIAID), a division of the Natio...
(Date:11/19/2009)...PRNewswire/ -- In response to an ever-increasing n...medicines, Operation Pangea II, involving 24 count...alth Organization,s International Medical Products...ht the dangers of buying medicines online. ,, T...s of arrests and the seizure of thousands of poten...
(Date:11/19/2009)...Nov. 19 Alexza Pharmaceu... its corporate presentation will be webcast live d...nference on Wednesday, December 2, 2009 at 9:00 a.... from The New York Palace Hotel in New York and wi...t and CEO. ,, To access the live presentation...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 1Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 2Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 3Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 1Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 2Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 3Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 4Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 5Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 1Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 2Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 3Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 4
(Date:11/21/2009)...1 Milvia Lopez, by her attorney MI...filed suit, in Supreme Court, New York County, bea...at while Ms. Lopez underwent a routine transesopha...ITAL , doctors used an HIV infected scope exposing...veral hours after being discharged from the proced...
(Date:11/21/2009)... based medical credentialing software company Inte... a partnerhsip with Amerinet, Inc., the leading he... help to transform quality care within the healthc...ember 21, 2009 -- ISG Group, LLC, doing business a... with Amerinet Inc., a leading national healthcare...
(Date:11/21/2009)...w Haven Dental Group merges their practice with th... (PRWEB) November 21, 2009...ers Dr. David Gibson, Dr. Dean Cloutier, Dr. John ... their growing practice with that of esteemed coll...decided he wanted to retire from dentistry in orde...
(Date:11/20/2009).... 20 The American Acad...ealth care reform legislation released this week t...urance individual coverage mandate. The actuaries ...l minimize adverse selection stemming from more re... bill. ,, "The individual mandate language shou...
(Date:11/20/2009)... Nov. 20 Rates of infect...ed in late October, but the pandemic flu virus con...age groups, including the elderly, according to a ...: DGX ), the world,s leading provider of diagnos...ts most recent Quest Diagnostics Health Trends(TM)...
Breaking Medicine News(10 mins):Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...Roche announced today that a total of,20 U.S. and ...eloda(R),(capecitabine) have been accepted for pre...mposium (SABCS) in San AntonioDecember 12-14, incl...cts to be presented at the meeting compare the imp...
... 9 , The following is being issued by Norma... Recently there has been a frenzy of articles in...elivery system. We are told there are 46 million,p...care,rescue plan passed within ninety days of Pres...
... Voonami, Inc., a leading provider of outsourc...nounced today the opening of their first of severa...r in Orem, UT. Voonami also announced two new ada...ty of 300 watts per square foot. , ...
... Despite the recent economic downturn, natural...e industry are still experiencing a wellness boom,...rowth. Natural Healers, the Internet,s top natural... centers to help prospective students interested i...
... Full Spectrum - a leading FDA software develo...h the latest information on code obfuscation techn...able now. , (PRWEB) Decem... the impact of using a basic software engineering ...
...Therapeutics, Inc.,(Nasdaq and MTA: CTIC) announce...ter studies utilizing Zevalin(R) ([90Y]-ibritumoma... of Hematology (ASH) 50th Annual Meeting in,San Fr...initial treatment in,15 patients with advanced sta...
Other Medicine News:Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Average Americans Without Health Insurance Are Young and Healthy With Above Average Incomes 2Health News:Voonami, Inc. Announces Three New Adaptive Data Centers 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection Technology 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 3Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 4Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 5
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: